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Abstract
Methotrexate (MTX) is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL). The accumulation of
MTX and its active metabolites, methotrexate polyglutamates (MTXPG), in ALL cells is an important determinant of its
antileukemic effects. We studied 194 of 356 patients enrolled on St. Jude Total XV protocol for newly diagnosed ALL with the
goal of characterizing the intracellular pharmacokinetics of MTXPG in leukemia cells; relating these pharmacokinetics to ALL
lineage, ploidy and molecular subtype; and using a folate pathway model to simulate optimal treatment strategies. Serial MTX
concentrations were measured in plasma and intracellular MTXPG concentrations were measured in circulating leukemia cells.
A pharmacokinetic model was developed which accounted for the plasma disposition of MTX along with the transport and
metabolism of MTXPG. In addition, a folate pathway model was adapted to simulate the effects of treatment strategies on the
inhibition of de novo purine synthesis (DNPS). The intracellular MTXPG pharmacokinetic model parameters differed
significantly by lineage, ploidy, and molecular subtypes of ALL. Folylpolyglutamate synthetase (FPGS) activity was higher in B
vs T lineage ALL (p,0.005), MTX influx and FPGS activity were higher in hyperdiploid vs non-hyperdiploid ALL (p,0.03), MTX
influx and FPGS activity were lower in the t(12;21) (ETV6-RUNX1) subtype (p,0.05), and the ratio of FPGS to c-glutamyl
hydrolase (GGH) activity was lower in the t(1;19) (TCF3-PBX1) subtype (p,0.03) than other genetic subtypes. In addition, the
folate pathway model showed differential inhibition of DNPS relative to MTXPG accumulation, MTX dose, and schedule. This
studyhasprovidednewinsightsinto the intracellular dispositionofMTXinleukemiacellsandhowitaffectstreatmentefficacy.
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Introduction
Methotrexate (MTX) is one of the primary anticancer agents
used for the treatment of acute lymphoblastic leukemia (ALL)
[1–3]. The ability of cells to accumulate intracellular polygluta-
mate metabolites of MTX (MTXPG) is an important factor in its
antileukemic effects [4]. Specifically, MTXPG inhibits the folate
pathway by competitively inhibiting several important enzymes
including: dihydrofolate reductase (DHFR), thymidylate synthase
(TS), glycinamide ribonucleotide transformylase (GART), and
aminoimidazole carboxamide ribonucleotide transformylase (AI-
CART). This inhibition leads to reduced or blocked TS and de
novo purine synthesis (DNPS), which are needed for DNA
synthesis. There is large variability in MTXPG accumulation and
a variety of studies have related differences in its accumulation to
ALL lineage, ploidy, molecular subtype, and folate pathway gene
expression [5–8]. Thus, developing a better understanding of the
underlying mechanisms responsible for these differences in cellular
disposition of MTX is important for understanding the basis for
inter-patient differences in MTX’s antileukemic effects and to
identify strategies to circumvent mechanisms of resistance.
Pharmacokinetic and pharmacodynamic modeling is a useful
approach to quantify the intracellular kinetics of MTX and to aid
in understanding the underlying mechanisms related to differences
in MTXPG accumulation [9]. For example, modeling can be
helpful in addressing whether higher accumulation of intracellular
MTXPG is related to higher formation of polyglutamates via
higher folylpolyglutamate synthetase (FPGS) activity, lower
degradation of polyglutamates via c-glutamyl hydrolase (GGH),
or differences in MTX influx or efflux from leukemic cells, In
addition, there are numerous models describing MTX inhibition
of target enzymes in the folate pathway [10–18], which can be
exploited to advance our understanding of how folate inhibitors
such as MTX alter folate homeostasis leading to its antileukemic
effects.
In an effort to better understand the underlying dynamics of the
observed differences in MTXPG accumulation along with their
differential effects on folate kinetics, we used a pharmacokinetic
model to characterize the disposition of plasma MTX and
intracellular MTXPG [9] along with a pharmacodynamic model
todescribe the dynamicsofperturbationsinthe folatepathway[12].
These models allowed us to relate differential disposition of
PLoS Computational Biology | www.ploscompbiol.org 1 December 2010 | Volume 6 | Issue 12 | e1001019intracellular MTXPG to changes in transport of MTX into and out
of leukemic blasts along with metabolism of intracellular MTXPG.
In addition, the folate pathway model allowed us to investigate how
this differential disposition of intracellular MTXPG alters folate
homeostasis and its downstream consequences.
Therefore, the objectives of this study were to determine the
intracellular pharmacokinetics of MTXPG in circulating leukemic
blasts, and to assess the relationship between these pharmacokinetic
parameters and covariates includingALL lineage, ploidy, molecular
subtype, and gene expression of and polymorphisms in or flanking
genes related to MTX transport and metabolism. In addition, we
analyzed the effects of intracellular MTXPG disposition, MTX
dose, and MTX infusion schedule on the folate pathway.
Results
This study included 194 patients with newly diagnosed ALL
who were enrolled on the St. Jude Total XV protocol and had
sufficient circulating ALL cells to permit serial measurement of
MTXPG in their leukemia cells. There were no differences in
demographics, lineage, ploidy, or molecular subtype between the
194 patients and all other patients on the Total XV protocol
(n=162). Not surprisingly, diagnostic WBC counts were higher in
the 194 patients than those in all other patients due to the need for
sufficient circulating ALL cells to perform the MTXPG assay
(Table S1). A summary of the demographic, lineage, chromo-
somal ploidy, molecular subtype, and randomized window therapy
arm for the patients included in this study are shown in Table 1.
Methotrexate Plasma and Leukemia Cell Intracellular
Pharmacokinetics
A total of 791 plasma samples in 194 patients were assayed to
determine the plasma MTX disposition. Figure 1A shows the
concentration vs time plot of these data along with the population
average model fit of the data sub-grouped by infusion length. The
median clearance of MTX was higher in the 24 hr infusion group
compared to the 4 hr infusion group (122.6 ml/min/m
2 vs
108.6 ml/min/m
2;p ,0.001).
A total of 732 peripheral blood leukemia cell samples in 194
patients were assayed for intracellular MTXPG disposition. Fixing
the plasma MTX pharmacokinetic parameters to each individual’s
estimates, the intracellular population pharmacokinetic parame-
ters for MTXPG were determined and the descriptive statistics of
the individual estimates (conditional means) are shown in Table 2.
In addition, the population estimates, relative standard error
estimates of the population estimates, inter-individual variability
estimates, and sensitivity analysis of the individual estimates are
summarized in Table S2. Figure 1 shows the concentration vs
time plot of intracellular MTX (or MTXPG1)( Figure 1B) and
total intracellular MTXPG2-7 (Figure 1C) along with the
population average model fit (for non-hyperdiploid B-lineage
ALL) of the data. In addition, several representative plots of
individual model fits to the data are shown in Figure S1.
Author Summary
One of the primary agents used in the treatment of
childhood acute lymphoblastic leukemia (ALL) is metho-
trexate (MTX). By better understanding its intracellular
disposition, we are able to better design treatments that
circumvent drug resistance and thus help improve ALL
cure rates. In this study, we develop a system of mathe-
matical models that describe the intracellular disposition
of MTX along with its inhibition of important biosynthetic
pathways necessary for cell division. First, we used the
models to describe the disposition of intracellular MTX in a
cohort of 194 patients enrolled on St. Jude Total XV
protocol for newly diagnosed ALL. The results of this
modeling allowed us to determine mechanisms of in vivo
variability in MTX accumulation. These mechanisms related
to both the influx and efflux of the drug along with the
enzymes related to its metabolism. Next, we used model
simulations to show the effects of changes in MTX dose
and schedule on its efficacy. The results of these
simulations show that longer infusions yield better efficacy
and that higher MTX doses can circumvent resistance
observed in ALL subtypes with lower intracellular MTX
accumulate. The results from this study provide new
insights into the design of more effective therapy for
pediatric ALL.
Table 1. Summary statistics of patients in this study.
Randomization Arm Window Therapy
1g / m
2 MTX infused IV over 24 hrs 1 g/m
2 MTX infused IV over 4 hrs
Number of peripheral blast samples (n) 99 95
Sex Male 47 55
Female 52 40
Self-Declared Race Caucasian 83 71
African American 12 18
Asian 2 2
Other 2 4
Lineage/Ploidy/Molecular Subtype B lineage
Hyperdiploid
31 29
B lineage Non-
Hyperdiploid
28 24
t(12;21)[ETV6-RUNX1]2 4 2 2
t(1;19)[TCF3-PBX1]6 8
T lineage 10 12
doi:10.1371/journal.pcbi.1001019.t001
Methotrexate Accumulation in Pediatric ALL
PLoS Computational Biology | www.ploscompbiol.org 2 December 2010 | Volume 6 | Issue 12 | e1001019Figure 1. MTX and MTXPG concentration vs time plots. (A) Plasma MTX concentration (mM) vs time (hrs). (B) Intracellular MTX (MTXPG1)
concentration in peripheral blood cells (pmol/10
9 cells) vs time (hrs). (C) Intracellular MTXPG2-7 concentration in peripheral blood cells (pmol/10
9 cells)
vs time (hrs). Black lines and circles represent the model fit and data given a 24 hour infusion and green lines and dimonds represent the model fit
and data given a 4 hour infusion. We plotted the MTXPG concentrations at fixed time points around each sampling time to prevent the samples from
the two different infusion groups from overlapping.
doi:10.1371/journal.pcbi.1001019.g001
Methotrexate Accumulation in Pediatric ALL
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It has been previously reported that there are significant
differences in intracellular MTXPG accumulation by ALL lineage,
ploidy, and molecular subtype [4,5,19]. Using the pharmacoki-
netic model of the intracellular disposition in peripheral blasts of
MTXPG, we quantified how differences in MTXPG disposition
related to the model estimated parameters describing MTXPG
influx, efflux, FPGS, and GGH activity.
MTX Influx and Efflux
ALL chromosomal ploidy exhibited differences in influx and
efflux parameters for MTX. Specifically, NET-influx was 2 times
higher (p,0.0009) in hyperdiploid ALL compared to non-
hyperdiploid ALL (Figure 2). In addition, we observed higher
efflux (1.8 times higher; p,0.003) and lower NET-influx (1.5 times
lower; p,0.02) in patients randomized to the 24 hr infusion
compared to the 4 hr infusion.
MTXPG Glutamylation and Degradation via Hydrolysis
The model parameters describing FPGS activity differed
significantly by ALL lineage and molecular subtype. Specifically,
the maximum FPGS activity was 2.1 times higher (p,0.0002) in B-
lineage ALL compared to T-lineage ALL. In addition, there was a
significant difference (p,0.0002) in the maximum FPGS activity
among the different molecular subtypes of ALL with the highest
activity in B-lineage hyperdiploid ALL followed in decreasing order
by B-lineage non-hyperdiploid, t(12;21) [ETV6-RUNX1], t(1;19)
[TCF3-PBX1], and T-lineage ALL (Figure 3A). These differences
translated to differential net accumulation (p,0.003) of MTXPG
(NET-PG) with highest accumulation in B-lineage hyperdiploid and
B-lineage non-hyperdiploid ALL, followed by t(12;21) [ETV6-
RUNX1], T-lineage, and t(1;19) [TCF3-PBX1] ALL (Figure 3B).
Gene Expression and Polymorphisms
We also investigated how the MTXPG model parameters
related to gene expression (mRNA) in ALL cells and germline
polymorphisms in or flanking genes related to MTX transport and
metabolism. These data were available for 168 and 190 of the
patients, respectively. First, we assessed how MTX transporter
gene expression and polymorphisms related to the model
estimated parameters for MTX influx and efflux. Specifically,
MTX influx (Vmax-in/Km-in) increased as the expression of SLC19A1
(probe set ID: 209775_x_at) increased (p,0.0005) and NET-
influx increased as the expression of SLC19A1 (probe set ID:
211576_s_at) increased (p,0.005) (Figure 4A–B). None of the
polymorphisms in or flanking transporter genes that we evaluated
were significantly related to the MTX influx or efflux parameters.
Next, we studied how FPGS and GGH gene expression and
polymorphisms related to the model estimated parameters for
FPGS and GGH activity. Specifically, net accumulation of
MTXPG (NET-PG) increased as the expression of FPGS (probe
set ID: 202945_at) increased (p,0.005) (Figure 4C). In addition,
two SNPs upstream of FPGS (DB SNP ID: rs1544105, 2782 base
pairs (bp) upstream and DB SNP ID: rs7033913, 4440 bp
upstream) showed a significant relation to maximum FPGS
activity (CC 2.6 times higher activity compared to TT:
p,0.005; CC 2.4 times higher activity compared to TT:
p,0.01, respectively) (Figure 5A–B).
Folate Pathway Simulations
We simulated the effects of differential MTXPG accumulation
on the MTX targets in the folate pathway to assess the effects of
varying dose and schedule on these targets. We used the previously
described enzyme kinetic parameters [12], the MTX and
MTXPG inhibition parameters [11], along with the MTX plasma
Figure 2. MTX net influx vs ALL ploidy. NET-influx (model parameter describing the net influx of MTX) vs ALL ploidy (hyperdiploid vs non-
hyperdiploid). Median, quartiles, non-outliers range (defined as 1.5 times the interquartile range), and outliers (plus-marks) are depicted for B-lineage ALL.
doi:10.1371/journal.pcbi.1001019.g002
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Figure 6 depicts an individual simulation of the dynamics of the
various folate components after infusion of 1 g/m
2 of MTX over
24 hours. This predicted a two-fold increase in DHF, a one-fold
decrease in 5mTHF, and only small changes in the remaining
folate components relative to the untreated steady-state levels.
Because MTXPG accumulation was significantly lower in T-
lineage ALL compared to B-lineage hyperdiploid ALL, we
Figure 3. MTX metabolizing enzyme model parameters vs ALL subtype. (A)V MAX FPGS vs molecular subtype. (B) NET-PG (net accumulation
of MTXPG) vs molecular subtype. Median, quartiles, non-outliers range (defined as 1.5 times the interquartile range), and outliers (plus-marks) are
depicted. The subtypes are defined as follows: BHD, B-lineage hyperdiploid ALL; BNHD, B-lineage non-hyperdiploid without the t(12;21) [ETV6-RUNX1]
or t(1;19) [TCF3-PBX1] translocation; ETV6-RUNX1, B-lineage non-hyperdiploid with the t(12;21) [ETV6-RUNX1] translocation; TCF3-PBX1, B-lineage non-
hyperdiploid with the t(1;19) [TCF3-PBX1] translocation; and T, T-lineage ALL.
doi:10.1371/journal.pcbi.1001019.g003
Methotrexate Accumulation in Pediatric ALL
PLoS Computational Biology | www.ploscompbiol.org 6 December 2010 | Volume 6 | Issue 12 | e1001019investigated how this differential accumulation affected the
inhibition of DNPS by comparing the simulated baseline DNPS
activity to its activity over a 72 hr post MTX treatment interval.
The simulations showed that there was both greater and longer
inhibition of DNPS in the B-lineage hyperdiploid group
(Figure 7A). Next we used simulations to compare the 44 hr
post MTX treatment inhibition of DNPS between different doses
(100 mg/m
2 to 5 g/m
2) and schedules (4 vs 24 hour infusions). As
expected, we observed that as we increased dose the simulations
predict greater inhibition of DNPS. We also observed greater
DNPS inhibition for doses infused over 24 hours compared to
4 hours. Specifically, while a 1 g/m
2 dose infused over 24 hours
was predicted to inhibit about three quarters of the patients’
DNPS more than 90%, it was predicted to take approximately a
2.5 g/m
2 dose infused over 4 hours to produce the same antifolate
effects (Figure 7B).
Discussion
MTX is one of the primary anticancer agents used to treat
children with ALL and its intracellular accumulation has been
shown to relate to its antileukemic effects [4]. The current study
allowed us to better understand the basis of differential MTXPG
accumulation and how it relates to ALL lineage, ploidy, molecular
subtype, gene expression, and genetic polymorphisms. We
accomplished this by developing innovative mechanistic pharma-
cokinetic and pharmacodynamic models of intracellular MTXPG
and its interaction with the folate pathway. This gave us a new
approach to describing the intracellular disposition of MTXPG
(e.g. influx, efflux, FPGS, and GGH activity) along with the effects
of MTXPG on the folate pathway. In addition, the model allowed
us to easily test hypotheses about which factors have the strongest
effects on MTXPG accumulation along with which MTX doses
and schedules more effectively inhibits the folate pathway.
Specifically, using the pharmacokinetic and pharmacodynamic
models, we were able to evaluate a) the mechanisms of
intracellular MTXPG accumulation, b) the causes of differential
accumulation by lineage, ploidy, and molecular subtype, c) the
difference between 4 vs 24 hour MTX infusion (validating
simulations in the previous study [9] which showed that longer
infusions of MTX at equivalent doses related to higher
accumulation of MTXPG), d) the relations between the pharma-
cokinetic and pharmacodynamic model parameters and mRNA
expression of and polymorphisms in and flanking related genes,
and e) how MTXPG accumulation affected target enzymes in the
folate pathway.
We observed that net influx of MTX was highest in B-lineage
hyperdiploid ALL cells which also corresponded to higher RFC
expression (SLC19A1). This relation has also been observed in our
previous modeling [9] and experimental studies [20]. In addition,
Figure 4. MTXPG model parameters vs gene expression in ALL blasts at diagnosis. (A) SLC19A1 expression (Probe Set ID: 209775_x_at) vs
Influx. (B) SLC19A1 (Probe Set ID: 211576_s_at) vs NET-influx. (C) FPGS expression (Probe Set ID: 202945_at) vs NET-PG.
doi:10.1371/journal.pcbi.1001019.g004
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to the infusion length of MTX. These differences are most likely
attributed to significantly different intracellular disposition of
MTXPG1 in the 4 hr infusion group compared to the 24 hr
infusion group. Specifically, while the population average
intracellular concentration of MTXPG1 is higher during the first
6 to 8 hours after the start of infusion in the 4 hour group
compared to the 24 hr group, the concentrations fall below that of
the 24 hour group for the remaining time (Figure 1B). These
differences could cause an overall increase in the efflux activity for
the individuals with higher intracellular concentrations over much
of the treatment interval of those in the 24 hr infusion group.
Figure 5. MTXPG model parameters vs germline SNPs. (A)V MAXFPGS vs FPGS SNP (DB SNP ID: rs1544105). (B)V MAXFPGS vs FPGS SNP (DB SNP
ID: rs7033913). The p-values were determined by the Kruskal-Wallis ANOVA.
doi:10.1371/journal.pcbi.1001019.g005
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accumulation with respect to ALL lineage, ploidy, and molecular
subtype. This is concordant with observed differences in FPGS
mRNA expression and SNPs in the gene encoding FPGS in both
the current study and others [21–23].
The folate pathway simulations allowed us to assess the effects of
differential MTXPG accumulation on the inhibition of important
biosynthetic pathways that are known targets of MTX. One
advantage of the modeling and simulation approach was that we
could efficiently evaluate multiple situations that would otherwise
be difficult, time consuming, and in many cases not practical from
a clinical trials perspective. In fact, this is the first time a system of
models combining the intracellular disposition of MTXPG and its
inhibition of the folate pathway have been used to aid in the
understanding of effective MTX therapy. There are two important
issues to consider when performing modeling and simulations: the
availability of and the sensitivity to the model parameters. Due to
the available studies of the folate cycle, there are numerous
published estimates of all the primary enzyme kinetic parameters
involved (see [12] for a summary). In addition, previous studies
have addressed the parameter sensitivity of these folate cycle
models by showing that in most cases the effects of changes in the
model parameters were local [12]. For example, it was shown that
changes in the enzyme kinetic parameters for DHFR had a
proportional effect on THF and a much smaller effect on other
folates. Figure S2 shows plots of the effects of changes in VMAX
DHFR and VMAX ACAIRT on their respective activities. For
these two parameters, only VmaxACAIRT had a proportional
effect on ACAIRT activity and the remaining effects were all
minimal. Thus, this effect is considered a local effect. Therefore,
the folate model is not sensitive to the parameter choice for
VMAXDHFR and only locally sensitive to the parameter choice for
VmaxACAIRT.
These simulations helped increase our understanding of how
MTXPG accumulation, MTX dose, and MTX schedule affect
antileukemic effects. In addition, our simulation results compared
qualitatively to previously published studies on MTX inhibition of
target enzymes, further validating them. Specifically, the simula-
tion which compared differential accumulation of intracellular
MTXPG by ALL lineage showed that in the T-lineage group only
about half of the individuals had DNPS inhibition greater than
90% at 44 hrs compared to more than three quarters of the
individuals in the B-lineage hyperdiploid group. Also, about half
the B-lineage hyperdiploid individuals’ DNPS was still inhibited
greater than 90% by 72 hours post treatment. These two results
are in line with our previously published results [24] which showed
that individuals with higher MTXPG accumulation were more
likely to achieve full inhibition of DNPS (defined as inhibition
greater than 90%). In addition, the simulations describing the
effects of MTX dose and schedule showed that there was increased
Figure 6. Individual simulated intracellular MTXPG and intracellular folate concentrations vs time. Dose: 1 g/m
2; Infusion time: 24 hrs.
Red: DHF; Green: THF; Light Blue: 5,10-CH2-THF; Magenta: 5mTHF; Yellow: 5,10-CH=THF; Dark Blue: 10f-THF; Solid Black: MTXPG1; Dashed Black:
MTXPG2-7.
doi:10.1371/journal.pcbi.1001019.g006
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schedules. These results are in line with our current clinically
measured changes in DNPS in the subset of our patients in which
DNPS was directly measured (unpublished data). These results
suggest that higher doses of MTX are needed to obtain similar
inhibition patterns with shorter (4H) compared to longer (24H)
infusions. A recent COG study randomized patients with ALL to
receive either a 2 g/m
2 dose infused for 4 hours or a 1 g/m
2 dose
infused for 24 hours [25]. The results of this study have yet to be
reported, but they will provide treatment outcome data that will
complement the current study.
In summary, our pharmacokinetic and pharmacodynamic
model of plasma MTX, intracellular MTXPG, and the folate
cycle provides an important new tool for elucidating mechanisms
underlying inter-individual differences in MTXPG intracellular
disposition and inhibition of target enzymes. Furthermore, this
model permits assessment of how the dosage or schedule of MTX
administration alters the delivery of active drug to leukemia cells of
Figure 7. Simulations of the effects of lineage and dosage on model estimated DNPS activity. The curves represent the median
and the shaded regions represent the quartiles of the results from the respective simulated patient populations. (A) Simulated percent change in
DNPS vs time after a 1 g/m
2 dose of MTX. Solid curve and Red shading: B-lineage Hyperdiploid; Dashed curve and Blue shading: T-lineage. (B)
Simulated percent change in DNPS at 42 hrs vs Dose. Solid curve and Red shading: 24 hr MTX infusion; Dashed curve and Blue shading: 4 hr MTX
infusion.
doi:10.1371/journal.pcbi.1001019.g007
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design of more effective therapy for pediatric ALL.
Methods
Patients
A total of356patients wereenrolled onSt. Jude Total XVprotocol
for newly diagnosed ALL between 2000 and 2007 which stratified
and randomized patients to receive MTX during the first day of
therapy [26]. This study included the 194 patients who had adequate
circulating leukemia cells for intracellular MTXPG quantification at
3 to 4 serial time points during the initial 42 hours of therapy.
Ethics Statement
The institutional review board approved the study, and informed
consent was obtained from parents/guardians or patients. This
study was compliant with the regulations of the Health Insurance
Portability and Accountability Act of 1996 (HIPAA).
Treatment Regimen and Sample Collection
Patients were randomized during the first day of therapy to
receive either 1 g/m
2 MTX infused intravenously over 24 or
4 hours. Serial plasma samples were obtained at 1, 4, 24, and
42 hours after the start of the MTX infusion and MTX
concentrations were assayed by the Abbottbase TDx-FPIA II
Figure 8. Model schematic. (A) The pharmacokinetic model for plasma and intracellular MTX and MTXPG [9]. The parameters are defined in the
text. The dashed line describing the efflux of intracellular MTX back to the plasma represents the fact that the system is uncoupled, i.e. we account for
the efflux of intracellular MTX but we do not explicitly account for its return to the plasma. (B) The folate pathway model [12] is modified to include
the pathways inhibited by MTXPG. The model parameters (described by arrows) are defined in the text and supplemental material.
doi:10.1371/journal.pcbi.1001019.g008
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leukemia cells were obtained at 1, 4, 24, and 42 hours after the
start of the MTX infusion. Intracellular concentrations of
MTXPG were assayed by HPLC as previously described [6,19].
Pharmacokinetic Model and Parameter Estimation
The pharmacokinetic model used to describe the plasma MTX
was a first-order two-compartment model (see first two equations
in (1)). The pharmacokinetic model to characterize the intracel-
lular disposition of MTXPG was previously described [9]. Briefly,
it involves two compartments, one for the intracellular concentra-
tion of MTXPG1, or intracellular MTX (the third equation in (1)),
and the second for the intracellular concentration of MTXPG2-7,
the sum of MTXPG2 through MTXPG7 (the fourth equation in
(1)), where the subscripts denote the number of glutamates
attached to each MTX molecule. A diagram of the model is
shown in (Figure 8A) and the model is described by the following
system of ordinary differential equations:
dMTX
dt
~{ kezk12 ðÞ MTXzk21MTXp
dMTXp
dt
~k12MTX{k21MTXp
dMTXPG1
dt
~
Vmax{inMTX=V
Km{inzMTX=V
zkpMTX=V{keffMTXPG1
{
Vmax{FPGSMTXPG1
Km{FPGSzMTXPG1
zkGGHMTXPG2{7
dMTXPG2{7
dt
~
Vmax{FPGSMTXPG1
Km{FPGSzMTXPG1
{kGGHMTXPG2{7
ð1Þ
The parameters are defined as follows: ke, k12, and k21 (1/hr) are
the first-order parameters describing the elimination of plasma
MTX and the transition between the central (MTX) and
peripheral (MTXp) compartments respectively; V (L/m
2) is the
systemic volume; Vmax-in (pmol/10
9 cells/hr) and Km-in (mM) are the
Michaelis-Menten parameters describing the active influx of MTX
into the leukemic blasts via the reduced folate carrier and various
ABC transporters; kp (1/hr) is the first-order passive influx
parameter; keff (1/hr) is the first-order efflux parameter; Vmax-FPGS
(pmol/10
9 cells/hr) and Km-FPGS (pmol/10
9 cells) are the
Michaelis-Menten parameters describing the FPGS activity; and
kGGH (1/hr) is the first-order parameter describing the GGH
activity. In addition, we defined several secondary parameters
which were combinations of the above parameters. These
included: Influx (Vmax-in/Km-in); NET-influx (Vmax-in/keff), the ratio
of maximum influx activity to efflux—the net influx of MTX;
FPGS (Vmax-FPGS/Km-FPGS); and NET-PG (Vmax-FPGS/kGGH), the
ratio of maximum FPGS to GGH activity—the net accumulation
of MTXPG.
We assumed that the amount of drug in the plasma significantly
exceeded the intracellular amount. Thus, we did not account for
the intracellular drug efflux into the plasma. This allowed us to
uncouple the system of four differential equations to two
independent systems—one for the plasma pharmacokinetics and
the other for the intracellular pharmacokinetics. First we estimated
the plasma MTX pharmacokinetics using the maximum a posteriori
probability (MAP) parameter estimation method implemented in
ADAPT 5 [27] along with the prior parameter distribution
obtained from previous St. Jude Total protocols [4]. Then, fixing,
per individual, these plasma pharmacokinetic parameters, the
intracellular MTXPG model parameters (both population esti-
mates and individual conditional means) were determined using
the Monte Carlo Parameter Expectation Maximization (MCPEM)
[28] with importance sampling population estimation algorithm in
ADAPT 5 [27]. This approach was used since, unlike the plasma
pharmacokinetics where we had abundant prior parameter
information from previous studies, minimal prior information on
the distribution of the intracellular MTXPG model parameters
was available. Due to the lack of identifiability of the passive influx
parameter kp we fixed it to 0.4 (1/hr) —its previously reported
value [29]. Finally, due to the known significant differences in the
intracellular disposition between B and T-lineage ALL, we fit each
lineage group separately in the population model. The individual
conditional means were used for comparison to covariates and for
the below described folate pathway simulations. The percent
relative standard error of the population estimated parameters, as
determined in ADAPT 5, was used to assess their sensitivity. In
addition, the individual conditional means were estimated ten
times using randomly chosen initial parameter values for each run.
From these runs the sensitivity of the individual conditional means
to changes in initial parameter values was determined by
calculating their average relative absolute error.
Folate Pathway Model
The model used to characterize the folate pathway was taken
from Nijhout et al. [12] and modified to include the inhibitory
effects of MTXPG on target enzymes (Figure 8B; equations in
Figure S3). Specifically, MTXPG was modeled to stoichiomet-
rically inhibit DHFR, TS, and AICART/GART via competitive
binding. We simulated the effects of MTXPG on the folate
pathway in each patient in the current study by using their
respective MTX plasma and intracellular MTXPG model
parameters along with published folate pathway enzyme
kinetic parameters [11,12]. We considered simulations over the
dose range from 100 mg/m
2 to 5 g/m
2 and with a 4 or 24 hr
infusion.
Gene Expression and Polymorphism Methods
Gene expression in ALL cells at diagnosis and germline SNPs in
or flanking (within 10,000 bp of the gene) folate transporter
(SLCO1B1, SLC19A1, ABCC1, ABCG2) and polyglutamation
(FPGS, GGH) genes were determined by Affymetrix HgU133A
Human GeneChip arrays and by Affymetrix 500K mapping array
genotyping as previously described [5,30,31].
Statistical Methods
Differences in the individual pharmacokinetic model parame-
ters (e.g. the conditional means determined by the above described
methods) due to lineage, ploidy, molecular subtype, gene
expression, and SNPs were determined by either the Kruskal-
Wallis ANOVA or the Mann-Whitney U-test.
Supporting Information
Figure S1 Representative concentration versus time plots for
plasma MTX and intracellular MTXPG model fits. For the
MTXPG concentration versus time plots the dashed lines
represent the intracellular MTX (or MTXPG1) and the solid lines
represent the intracellular MTXPG2-7 concentration. A) B-lineage
Hyperdiploid, 24 hr MTX infusion. B) B-lineage Hyperdiploid,
4 hr MTX infusion. C) B-lineage Non-Hyperdiploid, 24 hr MTX
infusion. D) B-lineage Non-Hyperdiploid, 4 hr MTX infusion. E)
T-lineage, 24 hr MTX infusion. F) T-lineage, 4 hr MTX infusion.
Found at: doi:10.1371/journal.pcbi.1001019.s001 (0.63 MB PDF)
Methotrexate Accumulation in Pediatric ALL
PLoS Computational Biology | www.ploscompbiol.org 12 December 2010 | Volume 6 | Issue 12 | e1001019Figure S2 Sensitivity analysis plots.
Found at: doi:10.1371/journal.pcbi.1001019.s002 (0.47 MB PDF)
Figure S3 Folate pathway model.
Found at: doi:10.1371/journal.pcbi.1001019.s003 (0.06 MB PDF)
Table S1 Summary statistics of all patients randomized in Total
XV subdivided by those included in the current study.
Found at: doi:10.1371/journal.pcbi.1001019.s004 (0.07 MB PDF)
Table S2 Population mean parameters for all the patients
(n=194) estimated by Monte Carlo Parameter Expectation
Maximization (MCPEM) with importance sampling population
estimation algorithm in ADAPT 5. RSE: relative standard error;
IIV: Inter-individual variability; CV: coefficient of variation. The
Individual Sensitivity Analysis is the median (over the popula-
tion—n=194) of the average (over 10 independent estimates each
using a different, randomly chosen, set of initial conditions) relative
absolute error in the parameter.
Found at: doi:10.1371/journal.pcbi.1001019.s005 (0.06 MB PDF)
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